On January 29, 2026, Athens Bioscience hosted its first-ever webinar for the Chinese market — and more than 1,000 professionals registered to attend. The session, presented in Mandarin by Athens' Beijing-based representative Sara Zhou, introduced the company's Athens Pure™ Immunogen Grade product line and explored a question that polyclonal antibody manufacturers increasingly cannot afford to ignore: does the purity of your immunogen actually determine the quality of your antibody?
The answer, as the webinar made clear, is yes — and the market knows it.
The Immunogen Problem No One Talks About
Polyclonal antibody production begins with immunization. The quality of the resulting antibody — its specificity, titer, and reproducibility from lot to lot — depends heavily on the antigen used as the immunogen. This is well understood in theory. In practice, however, most manufacturers still source research-grade proteins as immunogens, accepting purity levels that may introduce off-target immune responses, reduce antibody specificity, and create batch-to-batch variability that compounds through every downstream step.
The consequences are real. Failed immunization campaigns waste animals, time, and reagents. Inconsistent antibodies force manufacturers into costly re-screening and re-validation cycles. And for IVD companies building commercial diagnostic assays around polyclonal antibodies, upstream variability in the immunogen translates directly into downstream risk in the finished product.
Despite this, immunogen purity has historically been difficult to verify. Conventional analytical methods like SDS-PAGE and densitometry provide only approximate measures of purity and cannot identify trace contaminants with precision. Manufacturers have been forced to trust supplier datasheets rather than independently verifiable compositional data.
That is starting to change.
Athens Pure™ Immunogen Grade: Purity You Can Verify
Athens Bioscience developed the Athens Pure™ Immunogen Grade line specifically to address this gap. These native human proteins are purified using classical protein chemistry techniques refined over 40 years of manufacturing experience, then verified using LC-MS/MS on a high-resolution Orbitrap platform. Compositional data is searched against the UniProt human proteome at a 1% false discovery rate, producing a detailed profile of exactly what is in each lot — and what is not.
What Makes Immunogen Grade Different
Every Athens Pure™ Immunogen Grade lot ships with a Certificate of Analysis that goes well beyond conventional documentation. The CoA includes the overall purity percentage of the target protein, a subclass distribution breakdown where applicable, identification of any contaminant proteins present with their relative abundance, and a description of the analytical method used. This level of transparency gives antibody manufacturers something they have rarely had before: the ability to make sourcing decisions based on verified compositional data rather than catalog specifications.
For example, an Athens Pure™ Immunoglobulin G (IgG) Fc Fragment, Immunogen Grade preparation achieves greater than 99% purity for the target protein, with trace immunoglobulins and light chain fragments each identified and quantified at fractions of a percent. That kind of precision matters when the goal is to raise highly specific polyclonal antibodies against a defined epitope.
A Conversation Across the Value Chain
The January webinar was not a solo presentation. Athens partnered with Yashraj Biotechnology Ltd. (YBL), a leading polyclonal antibody manufacturer headquartered in Navi Mumbai, India, and a long-standing Athens customer. Founded in 1999, Yashraj supplies antigens, polyclonal antibodies, and related IVD raw materials to many of the world's top 20 diagnostics companies. The company holds ISO 13485 and ISO 9001 certifications and operates through subsidiaries in Germany and the United States.
Why the Joint Format Worked
The pairing was deliberate. Athens presented the upstream science — how immunogen-grade proteins are purified, analyzed, and documented. Yashraj presented the downstream reality — what happens in the immunization suite, the screening lab, and the production floor when the starting antigen is cleaner and better characterized.
This kind of cross-value-chain conversation resonated with the audience for a reason. Polyclonal antibody manufacturers in China and across the Asia-Pacific region operate in an increasingly competitive environment. IVD regulatory expectations are tightening. End customers are demanding more reproducible diagnostic performance. And the global supply chain for native human proteins is under pressure from geopolitical disruption and raw material scarcity. In this context, the choice of immunogen supplier is not a commodity decision — it is a strategic one.
What the Attendance Numbers Tell Us
One thousand registrants for a first-time webinar by a U.S.-based protein manufacturer, presented in Mandarin, on the relatively specialized topic of immunogen purity — that is a number worth pausing on.
It suggests several things about the current state of the polyclonal antibody market in China. First, there is active, unmet demand for higher-quality immunogen solutions. Second, manufacturers are looking beyond their traditional domestic supply chains for differentiated raw materials. Third, the market is ready for the kind of analytical transparency that Athens Pure™ Immunogen Grade products provide. And fourth, the combination of webinar format and localized content — Sara Zhou presenting in Mandarin with a trusted industry partner — removed the access barriers that often prevent smaller international suppliers from reaching the Chinese market.
For Athens Bioscience, the webinar confirmed what its growing China order book had already suggested: this market is paying attention.
What Comes Next
Athens Bioscience is building on this momentum. CEO John Mitchell and Sara Zhou will attend CACLP 2026 — the 23rd China International In Vitro Diagnostic Expo — in Xiamen from March 21–23, where they will meet directly with IVD manufacturers, academic researchers, and distribution partners. The company's regional distributor network in China has been growing steadily since mid-2025, with retail sales accelerating as partners complete product onboarding to local e-procurement platforms.
For polyclonal antibody manufacturers evaluating their immunogen supply chain, the message from Athens' first China webinar was clear: purity is not a specification on a datasheet. It is a measurable, verifiable attribute that directly impacts your product quality, your production economics, and your competitive position.
That is the Athens standard.